hotspot -WSS

hotspot

author：explore 2025-10-01 20:15:21 - browse：766

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Virginia high school admissions case could be legal follow
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

entertainment

Wikipedia

WSS

New weight loss drugs vying to be the next Wegovy or Mounjaro

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Long Covid needs a new name — and a new frame

New weight loss drugs vying to be the next Wegovy or Mounjaro

Pig kidney works a record two months in donated body

Readout Newsletter: The latest on Moderna, Apellis, and Merck

hotspot

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

In Memoriam: Notable people who died in 2023

Three trends to watch in biotech in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

CRISPR gene editing developments we’re watching in 2024

What does generative AI mean for health care? We asked experts

Acelyrin, a rare IPO success, stumbles in its first big test

Jerome Adams on the need for new antivirals for Covid

Food makers tried to stack nutrition panel with preferred experts

Cancer drug shortages should be causing more outrage

SEC charges former device maker CEO with $41 million fraud

entertainment

Will the IRA bring competition to the biologics market?

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Prime Medicine, Myeloid Therapeutics clash over genome

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

How medical schools plan to diversify without affirmative action

Pig kidney works a record two months in donated body

leisure time

entertainment

Wikipedia

knowledge